Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.

Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO ...

A REIT's debt levels, interest rate issues and financial performance are important factors when deciding which DST with a 721 ...

US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS: Basel Tuesday, September 17, 2024, 10:00 Hrs [IST] Roche announced that the United States ...

PPMS typically includes a steady loss of function from the onset of symptoms. The vast majority of people with MS receive an ...

Other MS patients, a minority, have a form of the disease that features gradually increasing progressive disability from onset—so-called primary progressive MS (PPMS). While effective disease ...